CoChat

BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer

Open access
Ramesh, Prashanthi, Di Franco, Simone, Atencia Taboada, Lidia, Zhang, Le, Nicotra, Annalisa, Stassi, Giorgio, Medema, Jan Paul · 2022 · Cell Reports

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index; none of the 28 sources its claims cite is checked for support yet.

Abstract

The heterogeneous therapy response observed in colorectal cancer is in part due to cancer stem cells (CSCs) that resist chemotherapeutic insults. The anti-apoptotic protein BCL-XL plays a critical role in protecting CSCs from cell death, where its inhibition with high doses of BH3 mimetics can induce apoptosis. Here, we screen a compound library for synergy with low-dose BCL-XL inhibitor A-1155463 to identify pathways that regulate sensitivity to BCL-XL inhibition and reveal that fibroblast growth factor receptor (FGFR)4 inhibition effectively sensitizes to A-1155463 both in vitro and in vivo. Mechanistically, we identify a rescue response that is activated upon BCL-XL inhibition and leads to rapid FGF2 secretion and subsequent FGFR4-mediated post-translational stabilization of MCL-1. FGFR4 inhibition prevents MCL-1 upregulation and thereby sensitizes CSCs to BCL-XL inhibition. Altogether, our findings suggest a cell transferable induction of a FGF2/FGFR4 rescue response in CRC that is induced upon BCL-XL inhibition and leads to MCL-1 upregulation.

Overview

CoChat Summary

TL;DR

In colorectal cancer models, low-dose BCL-XL inhibition with A-1155463 triggers an FGF2/FGFR4-dependent rescue response that stabilizes MCL-1 and limits apoptosis. FGFR4 inhibition sensitizes CSCs and patient-derived tumor organoids to A-1155463 in vitro and delays tumor outgrowth in vivo.

Key findings

  • A screen of 1,402 inhibitors in Co01 spheroids with 5 nM A-1155463 (an EC10 dose giving an average 8% viability decrease) identified 81 hits at Z score ≥2; 15% targeted Aurora kinases, and many targeted RTKs including VEGFR, PDGFR, FGFR, and c-kit. Ki8751, axitinib, nintedanib, and golvatinib validated, but golvatinib was excluded because it did not significantly induce caspase-3 in CSCs; Bliss scores >10 indicated synergy.
  • FGFR4 was the highest expressed target in Co01 cells and patient-derived tumor organoids. Selective FGFR4 inhibitors BLU9931 and H3B-6527 potentiated A-1155463-induced cytotoxicity and caspase-3 activation in TOP-GFP-high CSCs, whereas the FGFR1/2/3 inhibitor AZD4547 did not synergize. In vivo, A-1155463 (1 mg/kg) plus H3B-6527 (5 mg/kg) significantly delayed Co01 tumor outgrowth versus vehicle, while single treatments did not deter growth at that time point; 1 mg/kg A-1155463 showed no platelet impact, whereas 5 and 25 mg/kg caused significant platelet loss within 6 h.
  • Low-dose A-1155463 induced MCL-1 protein by 4 h without increasing MCL1 mRNA; FGFR4 inhibition or shFGFR4 knockdown prevented this upregulation. A-1155463 induced FGFR4 and ERK phosphorylation but not AKT; conditioned medium transfer induced MCL-1 in HCT116 and SW948 cells, blocked by H3B-6527 or trametinib; FGF2 treatment increased MCL-1, and shFGF2 blocked A-1155463-induced MCL-1. The MCL-1 inhibitor AZD-5991 plus low-dose A-1155463 produced an approximately 50-fold shift in EC50.
  • The combinations did not sensitize normal colon organoids or human platelets.

Methods

  • Drug screen: Co01 and Co01-BCL-XL spheroids were seeded at 4,000 cells/well, treated with 1,402 inhibitors at 1 µM alone or with 5 nM A-1155463 for 48 h, and viability measured by CellTiter-Blue. Data were Z score normalized; median Z′ factor was 0.73; hits had Z score ≥2 and were excluded if they also affected the BCL-XL-overexpressing line.
  • Validation: Co01 spheroids, patient-derived CRC organoids (P6T, P9T, P16T, P24aT), normal colon organoids, and human platelets were treated in dose-response or matrix titrations; synergy used the Bliss independence model with scores >10 considered synergistic. FACS measured activated caspase-3 in TOP-GFP high/low populations; immunoblot, qRT-PCR, shRNA knockdown, and supernatant transfer assessed mechanism. In vivo: NSG mice for platelet toxicity and NOD/SCID mice with subcutaneous Co01 tumors received A-1155463 (1 mg/kg) and/or H3B-6527 (5 mg/kg) intraperitoneally three times weekly for 3 weeks.
  • RNA-seq was performed on Co01 cells (GEO: GSE159504); patient-derived organoid expression data were analyzed via the R2 platform (GSE64392).

Limitations

  • Stated: the authors cannot rule out FGFR-independent MCL-1 stabilization, such as displacement of BAX/BAK from BCL-XL to MCL-1 leading to stabilization by displacing NOXA or MULE. The in vivo experiment was limited in numbers and did not induce a dramatic reduction in tumor growth rate with combination treatment; more extensive in vivo testing is needed.
  • Stated/evident: the screen and validation used standard culture medium containing FGF2, though the authors also observed FGFR4-dependent MCL-1 induction and combination efficacy without exogenous FGF2. In vivo, FGFR4 inhibition alone had variable effects, with some tumors showing increased growth upon H3B-6527 treatment, possibly via stromal or non-tumor-cell effects that need further exploration.
  • Evident from the text: FGFR4 inhibition showed significant but not complete prevention of MCL-1 upregulation in supernatant-transfer experiments, suggesting other receptors or factors may contribute; the paper also notes that MCL-1 targeting in the intestine may have detrimental side effects, including compensatory proliferation and carcinogenesis in MCL-1-deficient models.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2022.110374

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY-NC-ND · From the PDF
Figure 1 Drug screen identifies compounds that synergize with low-dose BCL-XL inhibition
Figure 1 Drug screen identifies compounds that synergize with low-dose BCL-XL inhibitionCC-BY-NC-ND · From the PDF
Figure 2 Selected hits induce CSC cell death in combination with A-1155463 while sparing normal colon organoids and platelets
Figure 2 Selected hits induce CSC cell death in combination with A-1155463 while sparing normal colon organoids and plateletsCC-BY-NC-ND · From the PDF
Figure 3 Ki8751, axitinib, and nintedanib in combination with A-1155463 induce synergistic cytotoxicity in patient-derived tumor organoids (A) Phase-contrast images of p16T human CRC organoids treated for 48 h with 10 m M axitinib alone and in combination with 30 nM A-1155463. Scale bars indicate 250 m m.
Figure 3 Ki8751, axitinib, and nintedanib in combination with A-1155463 induce synergistic cytotoxicity in patient-derived tumor organoids (A) Phase-contrast images of p16T human CRC organoids treated for 48 h with 10 m M axitinib alone and in combination with 30 nM A-1155463. Scale bars indicate 250 m m.CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF
Figure 5 BCL-XL inhibition induces an FGFR4-mediated rescue response
Figure 5 BCL-XL inhibition induces an FGFR4-mediated rescue responseCC-BY-NC-ND · From the PDF
Figure S1 Co01 BCL-XL is resistant to A-1155463, related to Figure 1.
Figure S1 Co01 BCL-XL is resistant to A-1155463, related to Figure 1.CC-BY-NC-ND · From the PDF
Figure S2 Validation of hits selected from the screen, related to Figure 2.
Figure S2 Validation of hits selected from the screen, related to Figure 2.CC-BY-NC-ND · From the PDF
Image 9
CC-BY-NC-ND · From the PDF
Image 10
CC-BY-NC-ND · From the PDF
Figure S5 FGFR4 specific inhibitors in combination with A-1155463 induce synergistic cytotoxicity in primary patient-derived tumor organoids, related to Figure 4. (A, B) 5 x 6 dose matrices of P6T, P9T and P24aT human CRC organoids treated with BLU9931 (A) and H3B-6527 (B) in combination with A-1155463 for 48h. % inhibition was calculated from viability data , after normalizing to control. Data represent the average of three independent experiments. Bliss synergy scores were calculated for each dose combination.
Figure S5 FGFR4 specific inhibitors in combination with A-1155463 induce synergistic cytotoxicity in primary patient-derived tumor organoids, related to Figure 4. (A, B) 5 x 6 dose matrices of P6T, P9T and P24aT human CRC organoids treated with BLU9931 (A) and H3B-6527 (B) in combination with A-1155463 for 48h. % inhibition was calculated from viability data , after normalizing to control. Data represent the average of three independent experiments. Bliss synergy scores were calculated for each dose combination.CC-BY-NC-ND · From the PDF
Figure S6 FGFR4 specific inhibitors in combination with A-1155463 induce synergistic cytotoxicity in vivo, related to Figure 4.
Figure S6 FGFR4 specific inhibitors in combination with A-1155463 induce synergistic cytotoxicity in vivo, related to Figure 4.CC-BY-NC-ND · From the PDF
Image 13
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 26 Not checked · 106 Own results and interpretations

67 more claims

Create a free account to see all 132 claims and to verify the 25 references still open.

See all claims — free account
  • It may state two separate claims as one. 48
  • Probably not a substantial claim. 18

Create a free account to see these claims.

Citations

Cites

Show all 52 references

Cited by

See all 26

Metadata

Authors
Ramesh, P., Di Franco, S., Atencia Taboada, L., Zhang, L., Nicotra, A., Stassi, G., & Medema, J. P.
Affiliations
  • Oncode Institute (NL)
  • University of Palermo (IT)
Corresponding author
Medema, Jan Paul
Venue
Cell Reports
Publisher
Elsevier BV
Published
2022-02
Volume
38
Issue
7
Pages
110374
ISSN
2211-1247 (ISSN-L)
OpenAlex
W4213342009
Cited by
26
References
53
Citations by year
2026: 7 · 2025: 8 · 2024: 2 · 2023: 7 · 2022: 2
FWCI
1.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Reports (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
Funders
  • University of Nebraska Medical Center
  • China Scholarship Council
  • Associazione Italiana per la Ricerca sul Cancro (21445, AIRC IG 21445, 5X 1000, AIRC5x1000)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
Keywords
BCL-XL inhibition, colorectal cancer, cancer stem cells, FGFR4, FGF2, BH3 mimetics, drug synergy, apoptosis, chemoresistance
MeSH terms
Axitinib, Aged, Animals, Colon, Drug Evaluation, Preclinical, Drug Synergism, Female, Humans, Indoles, Isoquinolines, Male, Middle Aged, Organoids, Neoplastic Stem Cells, Colorectal Neoplasms, Mice, SCID, Mice, Inbred NOD, Cell Death, Cell Line, Tumor, bcl-X Protein, Mice, Receptor, Fibroblast Growth Factor, Type 4, Benzothiazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.